Effectiveness of a structured caregiver support program for caregivers of people with Alzheimer's disease: A mixed methods study.

Geriatr NursJul 1, 2026 (epub)
Clinical ResearchGeriatricsPsychiatry

Hande Kirisik Surer, Nilufer Korkmaz Yaylagul

✦ AI-curated · Sources linked

In 30 seconds

This randomized controlled trial evaluated the Structured Caregiver Support Program (SCSP) for informal caregivers of individuals with Alzheimer's disease. The study found that SCSP significantly reduced caregiver burden and improved psychological well-being and resilience, with effect sizes ranging from 0.921 to 2.134, indicating a large impact.

Key findings

  • SCSP significantly reduced caregiver burden compared to the control group (p < 0.05).
  • Psychological well-being improved significantly in the intervention group (p < 0.05).
  • Effect sizes for post-test comparisons ranged from 0.921 to 2.134, indicating large effects.

Why it matters

Understanding effective support programs for caregivers is crucial, as they play a vital role in the care of individuals with Alzheimer's disease. Improved caregiver well-being can enhance the quality of care provided.

Source

PubMed · PMID 42379112

Published in Geriatr Nurs. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Geriatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.